Search

Issue
Title
Authors
Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study
Sokolova T.N., Solov'eva T.I., Aleksakhina S.N., Janus G.A., Goryainova A., Gluzman M.I., Orlova R.V., Stukan A.I., Zukov R.A., Zyuzyukina A.V., Murunova Y.N., Sultanbaev A.V., Vorobeva E.N., Mikhaevich L.M., Pyliv V.N., Lysenko A.N., Khachmamuk Z.K., Kozlov A.E., Bakharev S.Y., Parsyan S.G., Rossokha E.I., Osidze L.D., Shumskaya I.S., Agaeva A.V., Kasmynina T.A., Klimenko V.V., Akhmetgareeva K.T., Vakhitova A.A., Chakhkieva M.D., Dmitriev V.N., Bakshun Y.I., Vasilyev A.E., Gasimly D.D., Kravchenko N.A., Maksimov D.A., Nesterova A.I., Sharvashidze I.O., Gadzaova C.H., Rakhmankulova G.G., Khamgokov Z.M., Amirkhanova I.K., Bembeeva L.V., Vladimirov V.I., Petrenko O. ., Ruskova N.G., Serikova E.L., Subbotina K.S., Tkachenko S.A., Chang V.L., Erdniev S.P., Barbara V.S., Vasilevskaya A.V., Mikheeva Y.V., Popova N.O., Startseva E.P., Fateeva A.V., Yukalchuk D.Y., Grechkina A.A., Musaeva K.S., Odintsova S.V., Stel'makh A.S., Khabibulaeva P.I., Khlobystina A.G., Shvaiko K.A., Basova E.A., Bogomolova I.A., Bolieva M.B., Goldberg V.E., Kibisheva M.V., Menshikov K.V., Ryazanov D.V., Stepanova M.L., Udalova Y.A., Shkradyuk A.V., Chapko Y.S., Shchukina A.A., Khabriev I.M., Kirtbaya D.V., Degtyarev A.M., Epkhiev A.A., Tyugina Y.A., Murachuev M.A., Togo A.V., Ievleva A.G., Imyanitov E.N.
PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer (Russian Translation of Cochrane Plain Language Summary)
Uvarova K.G.
Experience in the treatment of radioinduced angiosarcoma of the breast in a patient with primary multiple lesions of the breast and bladder. Case report
Semenov E.V., Gasymly D.D., Zyuzyukina A.V., Zukov R.A.
Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice. Observational study
Sultanbaev A.V., Menshikov K.V., Musin S.I., Nasretdinov A.F., Fatikhova A.A., Izmailov A.A., Lipatov O.N., Ayupov R.T., Sultanbaeva N.I., Menshikova I.A., Serebrennikov G.A.
Management of patients with hormone receptor-positive HER2-negative metastatic breast cancer: data of randomized trials and real-world evidence
Editorial B.
Analysis of the complications of endocrine therapy with tamoxifen in breast cancer: clinical and pharmacogenetic aspects. Prospective pharmacogenetic cohort study
Savelyeva M.I., Golubenko E.O., Sozaeva Z.A., Poddubnaya I.V., Korennaya V.V.
A population-based portrait of breast cancer in russia: a cancer register-based analysis in russian
Poddubnaya I.V., Kolyadina I.V., Kalashnikov N.D., Borisov D.A., Makarova M.V.
The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
Shlivko I.L., Garanina O.E., Artamonova E.V., Ganshina I.P., Zhukova L.G., Koroleva I.A., Michenko A.V., Semiglazova T.Y., Filonenko D.A.
Avastin in clinical chemotherapy of malignant tumors
Gorbunova V.A.
The analysis of the relationship between transferrin receptor 1 (TfR1) and clinical, morphological and immunophenotypic characteristics of breast cancer: retrospective cohort study
Chulkova S.V., Sholokhova E.N., Poddubnaya I.V., Stilidi I.S., Tupitsyn N.N.
Current treatment aspects of hormone-dependent ERBB2-negative metastatic breast cancer: overall survival outcomes
Snegovoy A.V., Kononenko I.B.
Complex radiologic imaging of early breast cancer (literature review)
Aliyeva G.S., Korzhenkova G.P., Kolyadina I.V.
Antitumor response and quality of life: is there a need to sacrifice? Clinical observation: long-term and safe control of the disease using a combination of ribociclib with letrozole. Case report
Grechukhina K.S., Vorontsova K.A., Filonenko D.A., Tyutyunnik P.S., Shchadrova V.V., Zhukova L.G.
Triple-negative breast cancer: new options for systemic targeted therapy. A review
Andreev D.A., Zavyalov A.A.
Innovations in practice. 5 years of palbociclib experience in the Russian Federation. Overview of web-conference took place on 8 October 2021
Editorial B.
Immunological heterogeneity of stage I breast cancer:biological, population-based and prognostic value (international cooperation experience)
Kolyadina I.V., Poddubnaya I.V., Van de Velde C.J., Kuppen P.J., Frank G.A., Komov D.V., Karseladze A.I., Bastiaannet E., Dekker-Ensink N.G.
Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III
Morozov D.A., Kolyadina I.V., Poddubnaya I.V., Ganshina I.P., Khokhlova S.V., Kоmetova V.V., Rodionov V.V.
Rare morphological forms of breast cancer: features of surgical approach
Vysotskaya I.V., Letyagin V.P., Kolyadina I.V., Martynova G.V.
The first results of the national programme for the diagnosis and treatment of HER2-positive breast cancer in Turkmenistan
Berdimyradova M.B., Khadjiev S.M., Khommadova D.N., Polatova G.O., Kakajanova A.O., Batyrov C.B., Penayev D.N., Agayeva B.G., Annaberdiyeva G.A.
Quality of life and overall survival are primary priorities of patients with advanced breast cancer: results of sociological research
Kolomejtseva A.A., Bokova S.E.
Classification of breast cancer subtypes based on RNA profiling and immunohistochemical methods: clinical and biological aspects: A review
Imyanitov E.N.
Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer
Kolyadina I.V., Danzanova T.Y., Khokhlova S.V., Trofimova O.P., Kovaleva E.V., Rodionov V.V., Poddubnaya I.V.
The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer
Gordeeva O.O., Kolyadina I.V., Zhukova L.G., Gan'shina I.P., Komov D.V., Meshcheriakov A.A.
The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
Kolyadina I.V., Poddubnaya I.V.
Predictive factors of achievement pathological complete response at neoadjuvant chemotherapy of primary operable breast cancer
Pavlikova O.A., Kolyadina I.V., Komov D.V., Vishnevskaya Y.V., Poddubnaya I.V.
Prognostic value of p53 expression in patients with stage I breast cancer
Kolyadina I.V., Poddubnaya I.V., Van de Velde C.J., Kuppen P.J., Liefers G.J., Dekker-Ensink N.G., Bastiaannet E., Van As-Sajet A., Prinse B., Engels C., Van Vlierberghe R., Komov D.V., Karseladze A.I., Ermilova V.D., Vishnevskaya Y.V., Frank G.A., Banov S.M.
Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
Editorial B.
The predictive value of digital mammography, breast ultrasound and their combination in the diagnosis of early breast cancer
Alieva G.S., Korzhenkova G.T., Kolyadina I.V.
The potential use of oncolytic viruses in breast cancer: historical aspects and future prospects (literature review)
Morozov D.A., Kolyadina I.V., Poddubnaya I.V., Chumakov P.M., Ilinskaya G.V., Bokhian V.Y., Sopova M.I.
PARP inhibitors in female reproductive system cancers
Pokataev I.A., Tyulyandin S.A.
Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype
Karabina E.V., Zhukova L.G.
The use of combined plastic interventions in the reconstruction of post-operative soft tissue defects of the chest wall in the surgical treatment of locally advanced breast cancer
Vashenko L.N., Daschkova I.R., Bakulina S.M., Andreyko E.A.
Squamous cell breast cancer: description of a rare clinical case
Zikiryakhodjaev A.D., Khakimova S.G., Rasskazova E.A., Saribekian E.K., Omarova D.F., Surkova V.S., Khakimova G.G.
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
Board E.
Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
Board E.
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review
Poddubnaya I.V., Gligorov J., Zhukova L.G., Kovalenko E.I., Frolova M.A.
Immunotherapy in combination with chemotherapy in triple-negative breast cancer - the first “target” therapy for the “target” patients’ population
Grechukhina K.S., Zhukova L.G.
Clinical and radiological evaluation the effectiveness of preoperative systemic therapy in different biological subtypes of breast cancer stages T1-3N0-1M0
Pavlikova O.A., Poddubnaya I.V., Kolyadina I.V., Abdullaev A.G., Komov D.V., Danzanova T.Y., Sinyukova G.T., Kozlov N.A., Ganshina I.P., Zhukova L.G., Aliyeva G.S., Kerimov R.A., Gordeeva O.O.
Brain metastases in her2-positive breast cancer: new opportunities for systemic therapy
Artamonova E.V., Manziuk L.V.
Male breast cancer: review of the literature
Nikolaev K.S., Semiglazov V.F., Semiglazov V.V.
Modern treatment possibilities of hormone receptor-positive advanced breast cancer in postmenopausal women
Jackisch C., Llombart-Cussac A.
Current approach to adjuvant therapy for breast cancer (a review)
Conte P., Guarneri V.
Breast cancer immunophenotype and its relationship with haematopoiesis
Ryabchikov D.A., Chulkova S.V., Shamilov F.A., Chanturia N.V., Zheltikov S.D., Tupitsyn N.N.
Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
Board E.
The relationship of GITR, Lag-3 and PD-1 expression with the main indicators of systemic and local immunity in patients with breast cancer
Tabakov D.V., Zabotina T.N., Chanturia N.V., Zakharova E.N., Vorotnikov I.K., Selchuk V.Y., Sokolovskiy V.V., Petrovsky A.V.
Ribociclib in 1st line HR+ breast cancer treatment
Zhukova L.G., Ganshina I.P., Gordeeva O.O., Lubennikova E.V.
Eribulin for the treatment of anthracyclineand taxane-resistant breast cancer: a big step forward towards problem solving
Artamonova E.V.
Circulating tumor cell: biology, methods of isolation, clinical significance in breast cancer
Nenahova Y.N., Lyadov V.K., Poddubnaya I.V.
New opportunities to improve of duration and quality of life: eribulin in the treatment of patients with advanced breast cancer
Semiglazova T.Y., Klyuge V.A., Semiglazov V.V., Teletaeva G.M., Krivorotko P.V., Dashyan G.A., Paltuev R.M., Tkachenko E.V., Donskikh R.V., Semiglazov V.F.
The role and assessment of morphological regression after neoadjuvant therapy in breast cancer patients
Frank G.A., Ilatovskaia M.E., Andreeva I.I., Zavalishina L.E.
Tumor biology or adjuvant systemic therapy: what determines the risk of recurrence in breast cancer stage I?
Kolyadina I.V., Poddubnaya I.V., Trofimova O.P., Frank G.A., Karseladze A.I., Komov D.V.
The results of Epidemiological HER2 screening program in patients with breast cancer in 2013
Frank G.A., Poddubnaya I.V., Yagudina R.I., Borisov D.A., Koroleva N.I.
Synchronous thyroid gland metastases from breast cancer. Case reports
Ognerubov N.A., Antipova T.S., Palkina E.E.
Breast cancer
Zhukova L.G., Andreeva I.I., Zavalishina L.E., Zakiriakhodzhaev A.D., Koroleva I.A., Nazarenko A.V., Paltuev R.M., Parokonnaia A.A., Petrovskii A.V., Portnoi S.M., Semiglazov V.F., Semiglazova T.I., Stenina M.B., Stepanova A.M., Trofimova O.P., Tyulyandin S.A., Frank G.A., Frolova M.A., Shatova I.S., Nevol’skikh A.A., Ivanov S.A., Khailova Z.V., Gevorkian T.G.
Opportunities for metastatic triple negative breast cancer therapy
Ganshina I.P., Gordeeva O.O., Manukyan M.S.
Case studies on clinical experience of targeted therapy ribociclib in combination with letrozole in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Frolova M.A., Kochetkova Y.I., Chubenko V.A., Volkov N.M., Moiseenko F.V., Garmarnik T.V., Ponomarenko D.M., Orlov A.E., Kostalanova Y.V., Makarycheva Y.Y., Nizegorodzeva A.A.
Perspectives of pharmacogenetics approach to personalized tamoxifen therapy
Savelyeva M.I., Ignatova A.K., Panchenko Y.S., Urvantseva I.A., Poddubnaya I.V.
Fulvestrant in endocrine therapy of recurrent and metastatic breast cancer
Vladimirova L.Y.
Features of surgical treatment of patients with breast cancer receiving preoperative systemic therapy
Kolyadina I.V., Poddubnaya I.V., Pavlikova O.A., Komov D.V.
Difficulties in treating patients with breast cancer in Russia: the resolution on the results of the Review Board
Artamonova E.V., Gorbunova V.A., Zhukov N.V., Manzjuk L.V., Manihas A.G., Paltuev P.M., Semiglazov V.F., Semiglazova T.Y., Stenina M.B., Tjuljandin S.A., Chubenko V.A.
Antiangiogenic therapy for breast cancer with triple negative phenotype
Ganshina I.P., Ivanova K.A., Gordeeva O.O., Arkhipov A.V., Zhukova L.G.
Can any breast skin thickening be staged as T4?
Amosova V.A., Petrovskii A.V., Karpova M.S., Ponedel’nikova N.V., Frolova M.A.
Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
Kolyadina I.V., Ganshina I.P., Kuzmicheva S.V., Tekeeva A.I., Kolokolov J.D., Volkonskii M.V., Poddubnaya I.V.
Opportunities of the pharmacogenetic approach to personalized tamoxifen breast cancer therapy: case reports
Savelyeva M.I., Dudina I.A., Zaharenkova J.S., Ignatova A.K., Ryzhikova K.A., Sozaeva Z.A., Kudlay D.A., Perfileva O.M., Poddubnaya I.V.
Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?
Zhukova L.G., Ganshina I.P., Khatkova E.I., Tikhomirova T.E., Kondratyeva O.E.
Internal mammary nodes metastases for breast cancer: whether the morphological verification is necessary?
Trigolosov A.V., Uimanov V.A., Chernikh M.V., Petrovskiy A.V., Nikitina E.A., Nechushkin M.I.
Cost-effectiveness of empegfilgrastim (Extimia®) for the prevention of severe neutropenia in patients with malignant neoplasm of female breast
Rudakova A.V., Tolkacheva D.G., Gavrilova O.N., Vaganov A.S.
Radiation-induced lung injury in breast cancer patients after breast conservation therapy
Trofimova O.P., Tkachev S.I., Ivanov S.M., Utkina V.L., Cheban O.I., Glebovskaya V.V.
Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials)
Kolyadina I.V., Poddubnaya I.V.
New chemotherapy options for triple-negative breast cancer (review of literature)
Sekundova M.A., Zdvizhkov A.M., Borisov V.I.
Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer
Samaneva N.I., Vladimirova L.I., Kolyadina I.V., Frantsiyants E.M., Storozhakova A.E., Bandovkina V.A., Kalabanova E.A., Kabanov S.N., Svetitskaya I.V., Tishina A.V., Ezhova M.O.
The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
Kovalenko E.I., Artamonova E.V., Karabina E.V., Andreiashkina I.I., Prokof’eva E.A., Popova N.O., Gaisina E.A., Evstigneeva I.V., Shaidorov M.V., Zhiliaeva L.A., Ponomarenko D.M., Khasanova A.I., Mukhametshina G.Z., Koziakov A.E., Vorotilina L.V., Povyshev A.I., Simolina E.I., Marfutov V.V., Kozlov D.V., Suslova I.R., Shikina V.E., Karandeeva T.V., Shepel’ A.O., Kramskaia L.V., Oskirko D.A., Frolova O.S.
Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
Gorbunova V.A., Kolyadina I.V., Kovalenko E.I., Manziuk L.V., Artamonova E.V., Zhukova L.G., Bolotina L.V., Semiglazova T.I., Manikhas A.G., Raevskaia N.A., Itkin I.M., Filonenko D.V., Zhilyaeva L.A., Gol'dberg V.E., Popova N.O., Ponomarenko D.M., Shikina V.E., Suslova I.R., Romanchuk O.V., Kozlov D.V., Rzaev A.S., Marfutov V.V., Andreiashkina I.I., Vladimirova L.I., Mitashok I.S., Tikhanovskaia N.M., Karabina E.V., Mukhametshina G.Z., Khasanova A.I., Safina S.Z., Shaidorov M.V., Morozov D.A., Prokof'eva E.P., Kramskaia L.V., Karandeeva T.V., Evstigneeva I.V., Ovchinnikova E.G., Klement'eva T.P., Khrupalo O.V., Tiuvinova E.V., Sherstnev V.M., Chernov I.S., Kolokolov D.D., Gaisina E.A., Levchenko N.V., Chubenko V.A., Povyshev A.I., Iudina I.V., Vorotilina L.V., Andreeva T.V., Tumanian G.S., Koziakov A.E., Gil'mutdinova L.A., Osipov M.A., Shatokhina A.S., Vazhenina A.A., Chichkanova A.S., Vladimirov V.I., Ivanov A.N., Belokhvostova A.S., Cherniakova E.M., Tul'china E.A., Maklashova S.A., Shkodenko O.N., Kostalanova I.V., Tarasova A.V., Kuz'mina E.S.
Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
Kolbin A.S., Mosikyan A.A., Balykina Y.E., Proskurin M.A.
The role of nab-paclitaxel in the treatment of patients with metastatic breast cancer
Frolova M.A.
The results of Epidemiological HER2 screening program in patients with breast cancer in 2014
Poddubnaya I.V., Frank G.A., Yagudina R.I., Koroleva N.I., Zavalishina L.E.
Experience of eribulin application in previously treated patients with metastatic or locally recurrent breast cancer under the clinical trial
Ahmetzanov F.S., Ahmetzanova F.F.
Bone mineral density in patient with breast cancer
Poddubnaya I.V., Kizhaev E.V., Kolyadina I.V., Banov S.M., Zhmaeva E.M., Secko M.A.
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice
Kolyadina I.V., Abidova N.R., Akopyan A.A., Antonova G.V., Arapova O.I., Bobrova E.A., Bolotina L.V., Valiakhmetova C.K., Vasilevskaya A.V., Vladimirova L.Y., Volkonskiy M.V., Ganshina I.P., Gudkova I.E., Dergunov A.S., Evstigneeva I.V., Egurenkova V.S., Emshanov A.V., Zhukova L.G., Zueva E.V., Karabina E.V., Kolokolov J.J., Kuzmicheva S.V., Kuchevskaya O.A., Luev I.A., Maistrenko K.S., Markizova E.V., Marfutov V.V., Medvedev S.P., Merzlikina Y.I., Nersesova T.A., Ovchinnikova E.G., Orlova S.A., Samaneva N.Y., Stativko O.A., Storozhakova A.E., Stroyakovskiy D.L., Sultanbaev A.V., Tekeeva A.I., Fadeeva N.V., Fedorova A.N., Shalaeva O.M., Shangina I.A., Shirokova O.N., Shumskikh A.R., Yakubova M.Z.
Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor
Ganshina I.P., Ivanova K.A., Lubennikova E.V., Arkhipov A.V., Zhukova L.G.
The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience
Kolyadina I.V., Bulavina I.S., Petkau V.V., Strakhova N.V., Gorbunova V.A., Kovalenko E.I., Manziuk L.V., Artamonova E.V., Zhukova L.G., Bolotina L.V., Gan'shina I.P., Semiglazova T.I., Manikhas A.G., Raevskaia N.A., Itkin I.M., Khokhlova S.V., Filonenko D.V., Gol'dberg V.E., Popova N.O., Ponomarenko D.M., Shikina V.E., Vladimirova L.I., Tikhanovskaia N.M., Karabina E.V., Mukhametshina G.Z., Khasanova A.I., Safina S.Z., Shaidorov M.V., Orlov A.E., Kostalanova I.V., Levchenko N.V., Osipov M.A., Karandeeva T.V., Evstigneeva I.V., Chernov I.S., Kolokolov D.D., Povyshev A.I., Shatokhina A.S., Cherniakova E.M., Shkodenko O.N., Kuz'mina E.S.
The effect of derivatives of 3-hydroxypyridine and succinic acids on depressive symptoms, pain intensity and quality of life after surgical treatment of breast cancer
Volchegorskii I.A., Vazhenin A.V., Zyuzina M.S.
Pharmacoeconomic characteristics of ixabepilone (Ixempra) monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
Kolbin A.S., Mosikyan A.A., Kurilev A.A., Balykina Y.E., Proskurin M.A.
The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
Bolotina L.V., Manziuk L.V., Gorbunova V.A., Kovalenko E.I., Mukhametshina G.Z., Khasanova A.I., Vladimirova L.Y., Mitashok I.S., Prokofyeva E.P., Evstigneeva I.V., Andreyashkina I.I., Abramova N.A., Popova I.L., Karabina E.V., Teterich A.A., Gaysina E.A., Chubenko V.A., Limareva S.V., Tikhanovskaya N.M., Storozhakova A.E., Samaneva N.Y., Svetitskaya Y.V., Snezhko T.A., Kalabanova E.A.
Neoadjuvant systemic therapy of HER2-positive breast cancer
Frolova M.A.
The main markers of the long-term efficiency of neoadjuvant chemotherapy in breast cancer (review of literature)
Semiglazov V.F., Semiglazov V.V., Paltuev P.M., Nikolaev K.S., Dashyan G.A.
The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia
Sokolova T.N., Aleksakhina S.N., Yanus G.A., Sultanbaev A.V., Menshikov K.V., Lysenko A.N., Zukov R.A., Zyuzyukina A.V., Murunova Y.N., Rossokha E.I., Bakharev S.Y., Basova E.A., Kasmynina T.A., Shumskaya I.S., Bakshun Y.I., Musaeva K.S., Khasanova A.I., Dmitriev V.N., Bolieva M.B., Gadzaova C.H., Petrenko O.L., Maksimov D.A., Vladimirov V.I., Goldberg V.E., Popova N.O., Kibisheva M.V., Khamgokov Z.M., Vasilyev A.E., Iyevleva A.G., Imyanitov E.N.
Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
Ganshina I.P., Gordeeva O.O., Manukian M.S.
Dermatomyositis and polymyositis in breast cancer patients: a case reports
Ganshina I.P., Zhukova L.G., Burnevitch E.Z., Gordeeva O.O., Kondratieva O.E.
Bioequivalence assessment of BCD-022 (trastuzumab, manufactured by JSC BIOCAD, Russia) as compared with Herceptin® (F.Hoffmann-La Roche Ltd., Switzerland), used in combination with paclitaxel in HER2-positive metastatic breast cancer patients: findings of the international, double-blind phase III clinical study
Ignatova E.O., Burdaeva O.N., Kopp M.V., Kotiv B.N., Udovitsa D.P., Stroiakovskii D.L., Alekseev S.M., Sheveleva L.P., Khorinko A.V., Shapovalova I.S., Moiseenko V.M., Ivanov R.A.
Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy
Krivorotko P.V., Burdaeva O.N., Nechaeva M.N., Frolova M.A., Kopp M.V., Abrosimova A.A., Ivanov R.A.
Quality of life is the fundamental criterion of the efficacy of targeted therapy in patients with metastatic Her2-positive breast cancer
Semiglazova T.Y., Dashyan G.A., Semiglazov V.V., Zhabina A.S., Osipov M.A., Kotova Z.S., Klimenko V.V., Krivorotko P.V., Semiglazov V.F.
Personalized approach to HER2-positive advanced breast cancertherapy
Stenina M.B.
Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
Board E.
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
Mazurina N.V., Artamonova E.V., Beloyartseva M.F., Volkova E.I., Ganshina I.P., Troshina E.A., Tjulandin S.A., Chubenko V.A.
The post-mastectomy syndrome: the secondary lympedema after the combined treatment of breast cancer (the literature review and own results)
Stepanova A.M., Merzlyakova A.M., Khulamhanova M.M., Trofimova O.P.
Soft tissue metastases of the gluteal region in HER2+ breast cancer: a clinical case
Kolyadina I.V., Ganshina I.P., Zhukova L.G., Abdullaev A.G., Andreeva Y.Y., Danzanova T.Y., Sinyukova G.T., Komov D.V., Kozlov N.A., Filonenko D.A., Gordeeva O.O., Lubennikova E.V.
Albumin-bound paclitaxel in the treatment of metastatic breast cancer
Artamonova E.V.
The results of epidemiological screening program of HER2 status in patients with breast cancer in the federal districts of the Russian Federation in 2015
Poddubnaya I.V., Frank G.A., Yagudina R.I., Koroleva N.I., Zavalishina L.E.
Stereotactic biopsy of breast lesions under x-ray control
Manikhas G.M., Safronova O.B., Khudjakova T.G., Barabanova L.P., Punanova N.J.
1 - 100 of 103 Items 1 2 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies